📈 STERIS earnings beat estimates at $2.94 per share.
💰 Revenue grew 8.8% YoY to $1.59 billion.
Bullish +55
STERIS (NYSE:STE) Director Sells $1,239,005.46 in Stock
AI-generated analysis
Key insights
📈 STERIS reported quarterly earnings of $2.94 per share, beating analyst estimates of $2.68 by $0.26.
💰 Revenue reached $1.59 billion for the quarter, exceeding expectations of $1.56 billion and growing 8.8% year-over-year.
📉 Director Mohsen Sohi sold 4,893 shares worth $1,239,005.46, reducing his ownership by 16.76% to 24,305 shares.
💵 The company declared a quarterly dividend of $0.69 per share with an ex-dividend date of November 17th.
🏦 Institutional ownership stands at 94.69%, with Benjamin Edwards Inc. increasing its stake by 28.1% in Q3.
📊 Analyst consensus rating is 'Moderate Buy' with a price target of $276.33, up from previous targets.
🔍 KeyCorp raised its price objective to $284.00 and maintained an 'overweight' rating on the stock.
📉 Wall Street Zen downgraded STERIS from 'strong-buy' to 'buy' in a recent research report.
🏭 STERIS provides infection prevention products and services for healthcare, pharmaceutical, and research industries.
📈 The company's market cap is $24.62 billion with a P/E ratio of 30.07 and a beta of 0.86.
📈 Bullish signals
📈STERIS beat earnings expectations with $2.94 EPS versus the consensus of $2.68, demonstrating strong operational performance.
💰Revenue of $1.59 billion exceeded analyst forecasts of $1.56 billion, indicating robust demand for its medical equipment and services.
📈The company achieved a net margin of 13.41% and a return on equity of 14.80%, reflecting efficient operations and profitability.
💰Year-over-year revenue growth of 8.8% highlights the company's ability to expand its business in the healthcare sector.
🏦Major institutional investors like Benjamin Edwards Inc. increased their stakes, signaling confidence in the company's long-term prospects.
💵The board declared a quarterly dividend of $0.69 per share, providing regular income to shareholders and validating cash flow strength.
🔍KeyCorp raised its price target to $284.00 and maintained an 'overweight' rating, reflecting positive analyst sentiment.
📉 Risk factors
📉Wall Street Zen downgraded the stock from a 'strong-buy' to a 'buy' rating, indicating some analysts see less upside potential.
📉Director Mohsen Sohi sold $1.24 million in shares, representing a 16.76% reduction in his personal holdings.
Article
STERIS plc (NYSE:STE) reported strong quarterly financial results, posting $2.94 in earnings per share which beat the consensus estimate of $2.68 by $0.26. The company generated revenue of $1.59 billion, surpassing analyst expectations of $1.56 billion, with a net margin of 13.41% and a return on equity of 14.80%. Quarterly revenue increased by 8.8% year-over-year compared to the same period last year when the company reported $2.47 EPS.
In addition to its earnings beat, STERIS declared a quarterly dividend payable on December 17th for stockholders of record on November 17th. The dividend amount is set at $0.69 per share, representing an annualized yield of 1.1% and a payout ratio of 32.74%. This financial commitment reflects the company's stable cash flow generation and shareholder return strategy.
Institutional investor sentiment remains robust with 94.69% of shares held by institutional investors and hedge funds. Several major firms increased their stakes in the third quarter, including Benjamin Edwards Inc., which boosted its position by 28.1%, and First Trust Advisors LP, which grew its holdings by 2.7%. New positions were also established by Advisors Asset Management Inc., Private Wealth Asset Management LLC, and Private Advisor Group LLC.
Wall Street analysts maintain a generally positive outlook on the stock with a consensus rating of 'Moderate Buy' and a price target of $276.33. While Wall Street Zen recently downgraded its rating from 'strong-buy' to 'buy', other firms like KeyCorp, Piper Sandler, and Morgan Stanley have maintained or upgraded their ratings, citing continued confidence in the company's growth trajectory.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
STERIS plc (NYSE:STE) reported strong quarterly financial results, posting $2.94 in earnings per share which beat the consensus estimate of $2.68 by $0.26. The company generated revenue of $1.59 billion, surpassing analyst expectations of $1.56 billion, with a net margin of 13.41% and a return on equity of 14.80%. Quarterly revenue increased by 8.8% year-over-year compared to the same period last year when the company reported $2.47 EPS.
In addition to its earnings beat, STERIS declared a quarterly dividend payable on December 17th for stockholders of record on November 17th. The dividend amount is set at $0.69 per share, representing an annualized yield of 1.1% and a payout ratio of 32.74%. This financial commitment reflects the company's stable cash flow generation and shareholder return strategy.
Institutional investor sentiment remains robust with 94.69% of shares held by institutional investors and hedge funds. Several major firms increased their stakes in the third quarter, including Benjamin Edwards Inc., which boosted its position by 28.1%, and First Trust Advisors LP, which grew its holdings by 2.7%. New positions were also established by Advisors Asset Management Inc., Private Wealth Asset Management LLC, and Private Advisor Group LLC.
Wall Street analysts maintain a generally positive outlook on the stock with a consensus rating of 'Moderate Buy' and a price target of $276.33. While Wall Street Zen recently downgraded its rating from 'strong-buy' to 'buy', other firms like KeyCorp, Piper Sandler, and Morgan Stanley have maintained or upgraded their ratings, citing continued confidence in the company's growth trajectory.
📈 STERIS earnings beat estimates at $2.94 per share.
💰 Revenue grew 8.8% YoY to $1.59 billion.
💵 Quarterly dividend declared at $0.69 per share.
🏦 Institutional ownership is 94.69% with increased stakes.
📊 Analyst consensus rating is 'Moderate Buy' at $276.33.
📈 STERIS reported quarterly earnings of $2.94 per share, beating analyst estimates of $2.68 by $0.26.
💰 Revenue reached $1.59 billion for the quarter, exceeding expectations of $1.56 billion and growing 8.8% year-over-year.
📉 Director Mohsen Sohi sold 4,893 shares worth $1,239,005.46, reducing his ownership by 16.76% to 24,305 shares.
💵 The company declared a quarterly dividend of $0.69 per share with an ex-dividend date of November 17th.
🏦 Institutional ownership stands at 94.69%, with Benjamin Edwards Inc. increasing its stake by 28.1% in Q3.
📊 Analyst consensus rating is 'Moderate Buy' with a price target of $276.33, up from previous targets.
🔍 KeyCorp raised its price objective to $284.00 and maintained an 'overweight' rating on the stock.
📉 Wall Street Zen downgraded STERIS from 'strong-buy' to 'buy' in a recent research report.
🏭 STERIS provides infection prevention products and services for healthcare, pharmaceutical, and research industries.
📈 The company's market cap is $24.62 billion with a P/E ratio of 30.07 and a beta of 0.86.
Bullish Signals
EPS beat at $2.94 vs $2.68 consensus.
Risk Factors
Wall Street Zen downgraded stock from strong-buy to buy.
Director Mohsen Sohi sold $1.24M in shares.
Bullish Signals
STERIS beat earnings expectations with $2.94 EPS versus the consensus of $2.68, demonstrating strong operational performance.
Revenue of $1.59 billion exceeded analyst forecasts of $1.56 billion, indicating robust demand for its medical equipment and services.
The company achieved a net margin of 13.41% and a return on equity of 14.80%, reflecting efficient operations and profitability.
Year-over-year revenue growth of 8.8% highlights the company's ability to expand its business in the healthcare sector.
Major institutional investors like Benjamin Edwards Inc. increased their stakes, signaling confidence in the company's long-term prospects.
The board declared a quarterly dividend of $0.69 per share, providing regular income to shareholders and validating cash flow strength.
KeyCorp raised its price target to $284.00 and maintained an 'overweight' rating, reflecting positive analyst sentiment.
Risk Factors
Wall Street Zen downgraded the stock from a 'strong-buy' to a 'buy' rating, indicating some analysts see less upside potential.
Director Mohsen Sohi sold $1.24 million in shares, representing a 16.76% reduction in his personal holdings.
STERIS (STE) has reaffirmed its commitment to shareholder returns by declaring a quarterly dividend of $0.69 per share, payable on December 17, 2026, to investors of record as of November 17. The company's stock recently traded at approximately $227.12, reflecting an 8% return over the past month despite a softer year-to-date trend and modest multi-year total shareholder returns.
Analysts highlight STERIS's strategic shift toward recurring revenue streams, with chemistries and services now accounting for roughly 80% of total revenue compared to about 20% a decade ago. This mix shift is expected to add stability to organic revenue growth and support operating leverage into earnings, underpinning the company's infection prevention niche in healthcare.
Valuation perspectives on STERIS present mixed signals. While some models suggest a fair value of $263 per share, implying the stock is undervalued by roughly 14%, others note that trading at approximately 27.5x earnings places the stock at a premium relative to the US Medical Equipment industry average of 23.8x.
Key risks to STERIS's narrative include potential margin compression from unexpected tariff costs and delays in large chemistry projects that could drag on cash generation. The elevated P/E ratio suggests limited room for error if earnings expectations soften, creating a divergence between growth-focused and value-based investment theses.
📈 STERIS declared $0.69 quarterly dividend payable Dec 17, 2026.
🔄 Recurring chemistries and services now represent roughly 80% of revenue.
💰 Shares trade at $227.12 with an 8% one-month return.
📊 Fair value models suggest stock is undervalued by about 14%.
⚠️ Tariff costs pose margin compression risk to profitability.
📈 STERIS declared a quarterly dividend of $0.69 per share payable on December 17, 2026, reaffirming its shareholder return policy.
🔄 The company has successfully shifted its revenue mix so that recurring chemistries and services now represent roughly 80% of total revenue.
💰 STERIS shares trade at approximately $227.12, posting an 8% one-month return despite a weaker year-to-date trend.
📊 Valuation models suggest a fair value of $263 per share, indicating the stock may be undervalued by about 14% based on recurring revenue stability.
⚖️ The stock currently trades at roughly 27.5x earnings, which is richer than the US Medical Equipment industry average of 23.8x.
⚠️ Potential margin compression from tariff costs remains a key risk that could impact STERIS's profitability if not managed effectively.
🏭 Delays in large chemistry projects pose a threat to cash generation and could disrupt the company's growth trajectory.
📉 The elevated P/E ratio suggests less room for error if earnings expectations soften compared to industry peers.
Bullish Signals
Declared quarterly dividend of $0.69 per share.
Risk Factors
Trades at 27.5x earnings vs 23.8x industry average.
High valuation limits room for error if earnings soften.
Tariff costs could squeeze margins more than expected.
Bullish Signals
STERIS reaffirmed its shareholder return policy with a declared quarterly dividend of $0.69 per share, payable on December 17, 2026.
The company achieved an 8% one-month share price return, demonstrating recent market confidence despite weaker year-to-date trends.
A significant mix shift toward recurring chemistries and services now accounts for roughly 80% of STERIS revenue, enhancing stability.
This recurring revenue model is expected to support operating leverage into earnings and add stability to organic growth.
Risk Factors
The stock trades at approximately 27.5x earnings, which is a premium compared to the US Medical Equipment industry average of 23.8x.
Elevated valuation suggests less room for error if earnings expectations soften or if the fair value narrative fails to materialize.
Tariff costs could squeeze margins more than expected, potentially undermining the company's profitability and growth story.
STERIS plc agreed to acquire Xodus Medical for USD 2.10 billion on October 12, 2026, a deal designed to expand its operating-room consumables portfolio. The transaction is expected to close by December 31, 2026, subject to regulatory approvals, and will be financed primarily with debt. Analysts view the acquisition as a logical addition to the company's healthcare business, with projections indicating Xodus could contribute USD 245 million in revenue and USD 135 million in adjusted EBITDA for calendar year 2026.
STERIS reported strong fiscal first-quarter 2027 results on August 5, 2026, posting adjusted earnings per share of USD 2.59 and revenue of USD 1.49 billion, representing a 7.30% year-over-year increase. The company is scheduled to report fiscal second-quarter 2027 results on November 4, 2026, with consensus estimates projecting USD 2.68 in earnings per share on USD 1.56 billion in revenue. Additionally, Assenagon Asset Management increased its stake in STERIS by 37.9% to 105,373 shares as of October 19, 2026.
STERIS stock trades at EUR 197.65 on the European market and USD 221.97 in the US market as of late October 2026, with a market capitalization of approximately USD 21.6 billion. The company expects to realize USD 300 million in cash tax benefits on a net-present-value basis, effectively reducing the purchase price of Xodus Medical to USD 1.80 billion. Upcoming earnings and the acquisition timeline remain key focal points for investors monitoring the healthcare specialty sector.
🤝 STERIS agreed to acquire Xodus Medical for USD 2.10 billion by December 31, 2026.
📈 Fiscal Q1 2027 adjusted EPS reached USD 2.59 with revenue up 7.30% year over year.
💸 Tax benefits of USD 300 million reduce the effective purchase price to USD 1.80 billion.
📊 Analysts project Xodus will contribute USD 245 million in revenue for calendar year 2026.
📉 STE stock trades at USD 221.97 with a market cap of USD 21.6 billion.
📈 STERIS agreed to acquire Xodus Medical for USD 2.10 billion to expand its operating-room consumables portfolio.
💰 The deal is expected to close by December 31, 2026, and will be financed primarily with debt.
📊 Fiscal first-quarter 2027 results showed adjusted EPS of USD 2.59 and revenue of USD 1.49 billion, up 7.30% year over year.
🔍 Analysts project Xodus will contribute USD 245 million in revenue and USD 135 million in adjusted EBITDA for calendar year 2026.
💸 STERIS expects USD 300 million in cash tax benefits, reducing the effective purchase price to USD 1.80 billion.
📈 Assenagon Asset Management increased its stake by 37.9% to 105,373 shares as of October 19, 2026.
🗓️ The company is scheduled to report fiscal second-quarter 2027 results on November 4, 2026.
💹 STERIS stock trades at EUR 197.65 in Europe and USD 221.97 in the US with a market cap of USD 21.6 billion.
📉 The 52-week trading range for STE is between USD 195.14 and USD 269.44.
Bullish Signals
Acquired Xodus Medical for USD 2.10 billion to expand portfolio.
Risk Factors
Acquisition financed with debt increases leverage and interest obligations.
Deal requires regulatory approval and closes by Dec 31, 2026.
Bullish Signals
STERIS agreed to acquire Xodus Medical for USD 2.10 billion, a strategic move to expand its operating-room consumables portfolio.
Fiscal first-quarter 2027 results beat expectations with adjusted EPS of USD 2.59 and revenue growth of 7.30% year over year.
Analysts view the Xodus acquisition as a logical addition to the healthcare business, projecting significant revenue contribution.
The company expects USD 300 million in cash tax benefits, effectively lowering the net cost of the acquisition to USD 1.80 billion.
Major institutional investor Assenagon increased its stake by 37.9%, signaling strong confidence in the company's trajectory.
Risk Factors
The Xodus Medical acquisition will be financed primarily with debt, which may increase leverage and interest obligations.
The deal is subject to regulatory approvals and must close by December 31, 2026, introducing execution and timing risks.
STERIS plc's STE Healthcare segment is demonstrating strong market adoption with significant revenue growth in the first quarter of fiscal 2027. Healthcare revenues rose 8% to $1.05 billion, driven by a 9% increase in consumables and a 10% rise in services, while capital equipment orders grew 4%. The segment achieved an EBIT margin expansion of 60 basis points to 24.8%, supported by higher volumes and pricing power, though partially offset by inflation and tariffs.
The Applied Sterilization Technologies (AST) segment continues to generate robust service revenues, reaching over $1 billion in fiscal 2026 with operating profits exceeding $500 million. In the first quarter of fiscal 2027, AST revenues increased 6% to $297.6 million, fueled by an 11% growth in services. While customers are currently reducing inventories following difficult prior-year comparisons, destocking is expected to ease in the second half of the year, promising improved growth prospects.
STERIS is expanding its operational footprint with a new $600 million formulated chemistries Center of Excellence in North Carolina, which will combine manufacturing, R&D, and distribution for Healthcare and Life Sciences products. This strategic investment is projected to generate more than $700 million in revenues. The company maintains a market capitalization of $21.18 billion and has delivered an average earnings surprise of 1.18% over the trailing four quarters.
📈 Healthcare revenues rose 8% to $1.05B driven by consumables and services growth.
💰 EBIT margin expanded 60bps to 24.8% via favorable mix and productivity gains.
📦 Capital equipment backlog grew to $444M reflecting strong order intake.
⚠️ Gross tariff costs reached $14M with management warning of persistent pressure.
📉 Shares lost 8.3% over the past year, underperforming industry and S&P 500.
📈 STERIS Healthcare segment revenues rose 8% to $1.05 billion in Q1 fiscal 2027, driven by 9% growth in consumables and 10% growth in services.
💰 The company expanded its Healthcare EBIT margin by 60 basis points to 24.8%, supported by favorable mix and productivity gains.
📦 Capital equipment backlog increased to $444 million, reflecting strong order intake despite shipment timing variations.
🔬 AST segment revenues grew 6% to $297.6 million in Q1 fiscal 2027, with services up 11% and operating profit above $500 million for the year.
🏭 STERIS announced a $600 million investment in a new formulated chemistries Center of Excellence in North Carolina to boost manufacturing capacity.
📉 Shares lost 8.3% over the past year, underperforming the industry's 7.7% growth and the S&P 500's 16.6% rise during the same period.
⚠️ Gross tariff costs reached $14 million in Q1 fiscal 2027, though partially offset by $4 million in refunds, with management warning of persistent cost pressures.
📊 The company holds a Zacks Rank #2 (Buy) and has delivered an average earnings surprise of 1.18% over the trailing four quarters.
Bullish Signals
Healthcare revenue rose 8% to $1.05B in Q1 fiscal 2027.
Healthcare EBIT margin expanded 60bps to 24.8% via volume/pricing.
Capital equipment backlog reached $444M, signaling robust demand.
AST segment revenue exceeded $1B with profit over $500M.
$600M NC investment projected to generate >$700M in revenue.
Risk Factors
Shares lost 8.3%, underperforming industry's 7.7% growth.
STERIS Healthcare segment revenues rose 8% to $1.05 billion in Q1 fiscal 2027, driven by strong growth in consumables and services.
The company expanded its Healthcare EBIT margin by 60 basis points to 24.8%, supported by higher volumes and pricing power.
Capital equipment backlog rose to $444 million, indicating robust demand for STERIS' capital equipment offerings.
AST segment generated over $1 billion in revenues in fiscal 2026 with operating profit exceeding $500 million.
STERIS announced a $600 million investment in a new formulated chemistries Center of Excellence in North Carolina, projected to generate more than $700 million in revenues.
Risk Factors
Shares lost 8.3% over the past year, significantly underperforming the industry's 7.7% growth and the S&P 500's 16.6% rise.
Inflation partly offset pricing and productivity gains in the Healthcare and Life Sciences segments, limiting further margin expansion.
STERIS plc reported strong fiscal 2027 first-quarter results, driven by a 7% year-over-year revenue increase to USD 1.50 billion and constant-currency organic revenue growth of 6%. The company posted quarterly earnings per share of USD 2.59, beating the consensus estimate of USD 2.54 by USD 0.05. This performance indicates robust underlying demand within its core medical devices and sterilization systems business.
The stock traded at USD 224.59 on September 4, 2026, positioning it in the middle of its 52-week range between USD 195.14 and USD 269.44. With a market capitalization of USD 21.9 billion, the company's recent earnings beat provides more weight to its fundamentals than the modest daily stock movement alone. Investors are focusing on the organic growth metric as a key indicator of sustained business health.
STERIS plc continues to leverage its product base in medical devices and sterilization systems, where volume trends are critical. The consistent delivery of clean current-period figures allows for direct comparison with prior-year quarters, reinforcing confidence in the company's operational execution despite broader market sentiment fluctuations.
📈 STE revenue rose 7% YoY to $1.5B in Q1 fiscal 2027.
💰 EPS hit $2.59, beating estimates by $0.05.
🌱 Organic revenue grew 6% on strong core demand.
🏥 STE operates in Health Care with medical devices focus.
💼 Market cap stands at $21.9B as of Sept 8, 2026.
📈 STERIS plc achieved a 7% year-over-year revenue increase to USD 1.50 billion in fiscal 2027 first-quarter results.
💰 The company reported quarterly earnings per share of USD 2.59, surpassing the consensus estimate of USD 2.54 by USD 0.05.
🌱 Constant-currency organic revenue growth reached 6%, signaling strong underlying demand in the core sterilization business.
📊 The stock traded at USD 224.59, sitting comfortably within its 52-week range of USD 195.14 to USD 269.44.
🏥 STERIS plc operates primarily in the Health Care sector, focusing on medical devices and sterilization systems.
💼 The company maintains a market capitalization of USD 21.9 billion as of September 8, 2026.
Bullish Signals
Revenue grew 7% YoY to $1.50B in Q1 fiscal 2027.
Bullish Signals
STERIS plc delivered a 7% year-over-year revenue increase to USD 1.50 billion in fiscal 2027 first-quarter results.
The company beat earnings per share consensus by USD 0.05, reporting USD 2.59 versus the expected USD 2.54.
Constant-currency organic revenue growth of 6% demonstrates strong underlying demand independent of currency or price effects.
STERIS plc (STE) is a healthcare company providing infection prevention products and services globally, operating through Healthcare, Applied Sterilization Technologies, and Life Sciences segments. The company offers essential items ranging from surgical tables and lighting to contract sterilization for medical device manufacturers, supported by recurring demand across the healthcare and life sciences sectors.
As of September 2026, STE pays a quarterly dividend of $0.69, resulting in an annualized rate of $2.58 per share and a current yield of 1.15% based on a stock price of approximately $224.59. The company maintains a conservative payout ratio of 30.7%, distributing less than one-third of its earnings to shareholders, which provides substantial financial room to sustain or grow the dividend even if earnings face pressure.
The company has demonstrated a strong track record of dividend growth, achieving a compound annual growth rate (CAGR) of 9.9% from 2011 through 2025. Over this period, the annual dividend per share increased from $0.64 to $2.40, with even the slowest growth year in 2021 outpacing inflation. This consistent growth makes STE attractive for investors seeking a rising income stream rather than a high initial yield.
STE is characterized by a beta of 0.914, indicating that its stock price moves slightly less than the broader market, which suits investors looking for dividend growth with reduced volatility. While the current yield is modest compared to high-yield alternatives, it sits above the stock's five-year average of 0.89%, suggesting the current entry point offers better income potential than recent historical norms.
📈 STE pays $2.58 annualized dividend with 1.15% current yield.
🛡️ Company maintains conservative 30.7% payout ratio ensuring dividend safety.
📊 STE achieved 9.9% CAGR in dividend growth from 2011 to 2025.
🏥 STE operates globally via Healthcare, Sterilization, and Life Sciences segments.
📉 STE beta of 0.914 offers lower volatility than the broader market.
📈 STERIS plc (STE) pays a quarterly dividend of $0.69, totaling an annualized rate of $2.58 per share with a current yield of 1.15%.
🛡️ The company maintains a conservative payout ratio of 30.7%, distributing less than one-third of earnings to support dividend safety and future growth.
📊 STE has delivered a compound annual dividend growth rate (CAGR) of 9.9% from 2011 to 2025, increasing the annual payout from $0.64 to $2.40 per share.
🏥 STERIS operates globally through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences, providing essential infection prevention products and contract sterilization services.
📉 With a beta of 0.914, STE stock exhibits lower volatility than the broader market, offering stability for income-focused investors.
💰 The current dividend yield of 1.15% is higher than the stock's five-year average of 0.89%, presenting a potentially attractive entry point for income growth strategies.
Bullish Signals
STERIS maintains a conservative payout ratio of 30.7%, leaving substantial earnings capacity to sustain and grow the dividend despite potential market headwinds.
The company has achieved a robust 9.9% compound annual growth rate in dividends over the past 15 years, demonstrating a strong commitment to increasing shareholder income.
The current dividend yield of 1.15% exceeds the stock's five-year average of 0.89%, indicating that the current price offers more income than recent historical norms.
STERIS operates in essential healthcare and life sciences sectors with recurring demand for infection prevention products and contract sterilization services, providing a durable business model.
STERIS plc reported strong first-quarter fiscal 2026 results, with total revenue growing 9% and constant currency organic revenue rising 8%. Gross margins expanded to 45.3%, driven by pricing power and productivity gains that outpaced inflation and tariff costs. Adjusted earnings per diluted share increased 15% year-over-year to $2.34, reflecting improved operational leverage and geographic mix.
The company highlighted robust performance across its Healthcare, AST, and Life Sciences segments. Healthcare capital equipment revenue grew 6% with a backlog exceeding $400 million, while AST services surged 13%. Life Sciences consumables drove growth, and backlog increased over 50% to $111 million. Free cash flow for the quarter reached $327 million, marking a strong start to the fiscal year.
Management updated its full-year outlook, anticipating as-reported revenue growth of 8% to 9% due to favorable currency rates, while maintaining constant currency organic revenue guidance at 6% to 7%. The company increased its free cash flow forecast by $50 million to $820 million for fiscal 2026. CFO Mike Tokich announced his departure after 18 years, with Karen Matson set to succeed him as the new CFO.
📈 Q1 2026 revenue grew 9% driven by volume and pricing.
💰 Gross margin expanded to 45.3% offsetting inflation and tariffs.
🚀 Free cash flow reached $327 million with outlook raised to $820M.
🏭 Healthcare equipment backlog exceeded $400 million with 14% order growth.
🔬 Life Sciences consumables backlog rose over 50% to $111 million.
📈 STERIS reported Q1 2026 total revenue growth of 9% and constant currency organic revenue growth of 8%, driven by volume and pricing.
💰 Gross margin expanded to 45.3%, up 20 basis points, as positive price and productivity gains offset inflation and tariff costs.
📊 Adjusted earnings per diluted share rose 15% year-over-year to $2.34 from continuing operations.
🚀 Free cash flow for the quarter reached $327 million, a very strong start to fiscal 2026.
🏭 Healthcare capital equipment revenue grew 6% with underlying order growth of 14% and a backlog over $400 million.
🔬 AST services revenue surged 13%, while Life Sciences consumables grew 8% with backlog up over 50% to $111 million.
💵 The company increased its full-year free cash flow outlook by $50 million to $820 million for fiscal 2026.
👔 CFO Mike Tokich announced his departure after 18 years, with Karen Matson named as the incoming CFO.
Bullish Signals
Revenue grew 9% and organic revenue up 8% in Q1 2026.
Risk Factors
Tariff cost estimate rose $15M to $45M for fiscal 2026.
Management adopted conservative stance on 6%-7% organic revenue guidance.
Bullish Signals
STERIS achieved a 9% total revenue growth and 8% constant currency organic revenue growth in Q1 2026.
Gross margin expanded to 45.3%, up 20 basis points, demonstrating strong pricing power and operational efficiency.
Adjusted earnings per diluted share increased 15% year-over-year to $2.34 from continuing operations.
Free cash flow for the quarter reached $327 million, reflecting strong earnings and working capital improvements.
Healthcare segment backlog exceeded $400 million with underlying order growth of 14%, indicating robust demand.
AST services revenue grew 13% driven by bioprocessing demand and stable medical device volumes.
Life Sciences backlog increased over 50% to $111 million, signaling strong future capital equipment sales.
Management raised the full-year free cash flow guidance by $50 million to $820 million for fiscal 2026.
Risk Factors
The company increased its tariff cost estimate by $15 million to $45 million for fiscal 2026 due to higher metal and copper tariffs.
Management noted general conservatism in maintaining the 6% to 7% constant currency organic revenue guidance despite a strong first quarter.
STERIS plc reported strong financial results for its fiscal 2027 first quarter ended June 30, 2026. Total revenue increased 7% year-over-year to $1.5 billion, driven by a 6% constant currency organic growth rate. Adjusted diluted earnings per share rose to $2.59, reflecting improved operational performance across its core segments.
The company's Healthcare segment led the growth with an 8% revenue increase to $1.05 billion, fueled by double-digit gains in service and consumable revenues. Applied Sterilization Technologies (AST) saw a 6% revenue rise, while Life Sciences grew 9%, primarily driven by capital equipment sales. Operating income expanded across all segments due to volume and price improvements.
STERIS announced a targeted restructuring plan to consolidate its formulated chemistries manufacturing into a new Center of Excellence in North Carolina. This initiative involves closing facilities in St. Louis and Plymouth, with expected pre-tax charges between $55 million and $70 million over time. Consequently, the company raised its full-year capital expenditure guidance to approximately $450 million.
Despite the restructuring costs and increased capex, STERIS maintained its full-year revenue and earnings guidance. The company reiterated expectations for as-reported revenue growth of 7-8% and adjusted EPS between $11.10 and $11.30. Management highlighted stable underlying demand and continued share gains in consumables as key drivers for navigating the complex operating environment.
📈 Revenue rose 7% YoY to $1.5 billion with organic growth of 6%.
💰 Adjusted diluted EPS increased to $2.59 per share.
🏥 Healthcare revenue grew 8% to $1.05 billion driven by services and consumables.
🔬 Life Sciences revenue jumped 9% led by a 17% surge in capital equipment.
🔄 Restructuring charges of $55-70 million announced with new North Carolina manufacturing center.
📈 Total revenue increased 7% year-over-year to $1.5 billion, with constant currency organic growth of 6%.
💰 Adjusted diluted EPS rose to $2.59 per share, up from $2.34 in the prior year period.
🏥 Healthcare segment revenue grew 8% to $1.05 billion, driven by 10% service and 9% consumable growth.
🔬 Life Sciences revenue increased 9% to $146.7 million, led by a 17% surge in capital equipment sales.
🏭 Applied Sterilization Technologies (AST) revenue grew 6% to $297.6 million despite a 13% drop in capital equipment.
🔄 A restructuring plan was announced to consolidate formulated chemistries manufacturing into a new North Carolina Center of Excellence.
💸 The company expects pre-tax restructuring charges of $55 million to $70 million, including $40-50 million in cash costs.
🏗️ Capital expenditure guidance was raised to approximately $450 million due to the new manufacturing investment.
📉 Free cash flow decreased to $279.6 million for the quarter, primarily due to lower working capital contributions.
🎯 Management reiterated full-year guidance with as-reported revenue growth of 7-8% and adjusted EPS of $11.10-$11.30.
Bullish Signals
Revenue grew 7% YoY to $1.5 billion.
Adjusted diluted EPS rose to $2.59.
Healthcare revenue surged 8% to $1.05 billion.
Life Sciences equipment revenue jumped 17%.
Company maintained full-year revenue and earnings guidance.
Risk Factors
Free cash flow declined to $279.6 million from $326.5 million.
Restructuring charges will total $55 million to $70 million.
Capital expenditures increased to $450 million from $375 million guidance.
STERIS plc (NYSE: STE) saw significant institutional activity in the first quarter, characterized by a sharp reduction in holdings by Krilogy Financial LLC, which cut its stake by 65.7% to just 1,752 shares worth $385,000. Conversely, major financial institutions increased their positions; Goldman Sachs Group Inc. grew its stake by 32.3% to acquire over 59,000 shares valued at approximately $55 million, while Jones Financial Companies Lllp and Woodline Partners LP also raised their holdings significantly.
The company's stock performance metrics indicate a current trading price of $215.59, trading below its 200-day moving average of $233.10 but above its 50-day average of $212.77. Financial health remains robust with a market capitalization of $21.01 billion, a current ratio of 2.09, and a low debt-to-equity ratio of 0.25. The company recently paid a quarterly dividend of $0.63 per share, resulting in an annualized yield of 1.2% with a payout ratio of 31.78%.
Analyst sentiment is mixed but generally leans positive, with an average rating of 'Moderate Buy' and a consensus price target of $278.00. While Wall Street Zen lowered its rating from 'strong-buy' to 'buy' and KeyCorp reduced its price objective, Piper Sandler maintains an 'overweight' rating with a $270 target. Insider trading activity included sales by VP John Adam Zangerle and Director Richard C. Breeden, who executed transactions under pre-arranged Rule 10b5-1 plans.
Assenagon Asset Management S.A. significantly increased its stake in STERIS plc (NYSE:STE) by 160.6% during the first quarter, purchasing an additional 30,104 shares to hold a total of 48,846 shares valued at $10.8 million. This move aligns with other major institutional investors who have recently added to their positions, including Norges Bank which established a new stake worth over $320 million in the fourth quarter, and AQR Capital Management which raised its holdings by 178.6%.
Other notable institutional activity includes Boston Partners initiating a position valued at approximately $159 million and Orbis Allan Gray Ltd boosting its stake by 36%. State Street Corp also increased its position by 6% in the fourth quarter. Collectively, these investors hold 94.69% of the company's outstanding stock, indicating strong institutional confidence in the medical equipment provider.
STERIS shares are currently trading with a market capitalization of $21.01 billion and a price-to-earnings ratio of 27.19. The company recently paid a quarterly dividend of $0.63 per share to investors of record on June 8th, resulting in an annualized yield of 1.2%. Analyst consensus remains moderately bullish with an average price target of $278.00, though recent ratings from KeyCorp and Wall Street Zen have been adjusted slightly downward.
Despite the strong institutional buying, insider selling activity was recorded in mid-June. VP John Adam Zangerle sold 1,419 shares for approximately $297,000 on June 15th, while Director Richard C. Breeden sold 1,481 shares for about $310,000 on June 2nd. These transactions were executed under pre-arranged Rule 10b5-1 trading plans and represent a small fraction of total insider ownership, which stands at 1.12%.
📈 Assenagon raised STERIS stake 160.6% to 48,846 shares in Q1.
🏦 Norges Bank added $320.3M position in Q4 signaling major interest.
📊 AQR increased holdings 178.6% to 1.18 million shares worth $291.7M.
💰 Boston Partners bought new stake valued at approximately $159 million.
📉 Orbis Allan Gray boosted position 36% to 2.1 million shares.
📈 Assenagon Asset Management raised its STERIS stake by 160.6% in Q1, adding 30,104 shares to a total holding of 48,846 shares.
🏦 Norges Bank initiated a new position valued at $320.3 million in the fourth quarter, signaling major institutional interest.
📊 AQR Capital Management increased its stake by 178.6% to own 1.18 million shares worth $291.7 million.
💰 Boston Partners purchased a new stake valued at approximately $159 million in the third quarter.
📉 Orbis Allan Gray Ltd boosted its position by 36% to hold 2.1 million shares valued at $504.5 million.
🏛️ State Street Corp increased its holdings by 6% in Q4, now owning 4.6 million shares worth $1.17 billion.
📈 Institutional ownership of STERIS stands at a high 94.69%, reflecting broad investor confidence.
💵 The company paid a quarterly dividend of $0.63 per share on June 26th with an annualized yield of 1.2%.
📉 VP John Adam Zangerle sold 1,419 shares for $296,968 under a pre-arranged trading plan on June 15th.
📉 Director Richard C. Breeden sold 1,481 shares for $310,284 on June 2nd under a similar trading plan.
📊 Insider selling totaled 7,328 shares valued at $1.55 million over the last three months.
🎯 Analyst consensus rating is 'Moderate Buy' with an average price target of $278.00.
Bullish Signals
Major investors like Norges Bank increased stakes in STERIS.
Assenagon Asset Management raised position by 160.6% in Q1.
State Street Corp boosted stake by 6% to $1.1B.
Healthy balance sheet: current ratio 2.09, debt-to-equity 0.25.
Dividend yield 1.2% with sustainable 31.78% payout ratio.
Risk Factors
VP Zangerle sold 1,419 shares for $296,968 in mid-June.
Director Breeden sold 1,481 shares for $310,284 on June 2nd.
Insiders sold 7,328 shares valued at $1.55 million last three months.
Bullish Signals
Major institutional investors including Norges Bank, AQR Capital Management, and Boston Partners have initiated or significantly increased their stakes in STERIS.
Assenagon Asset Management raised its position by 160.6% in the first quarter, demonstrating strong conviction in the company's prospects.
State Street Corp boosted its stake by 6% in the fourth quarter, adding to a substantial existing holding of over $1.1 billion.
The company maintains a healthy balance sheet with a current ratio of 2.09 and a low debt-to-equity ratio of 0.25.
STERIS pays a consistent quarterly dividend with an annualized yield of 1.2% and a payout ratio of 31.78%, indicating sustainable cash flow.
Risk Factors
VP John Adam Zangerle sold 1,419 shares for $296,968 in mid-June, representing a 3.87% decrease in his personal position.
Director Richard C. Breeden sold 1,481 shares for $310,284 on June 2nd, reducing his ownership by 3.66%.
Insiders collectively sold 7,328 shares valued at $1.55 million over the last three months, though this represents only 1.12% of total stock.
STERIS plc's STE Healthcare segment is demonstrating strong market adoption with infection prevention consumables and capital equipment driving growth. In the fiscal fourth quarter, Healthcare revenues increased 7% to $1.14 billion, fueled by a 9% rise in services, 7% growth in consumables, and 6% growth in capital equipment. For the full year, Healthcare revenues reached $4.21 billion with service growing 12% and capital equipment up 6%. The Applied Sterilization Technologies (AST) segment is also gaining traction, particularly in ethylene oxide sterilization for biopharmaceutical manufacturers. Fiscal 2026 AST revenues increased 10% to surpass $500 million in operating profit, with fourth-quarter revenues rising 6% year over year to $289.2 million driven by an 11% increase in services revenue.
Despite these operational strengths, the company faces headwinds from macroeconomic volatility and unfavorable foreign exchange rates which impact reported results and competitiveness. Additionally, STERIS is dealing with increasing costs due to new U.S. government tariffs, with incremental tariff costs of approximately $46 million in 2026 expected to trim margins by 80 basis points. These factors have led to an escalation in operating expenses, including a 5.4% increase in selling, general and administrative expenses and a 4% rise in research and development expenses, resulting in an adjusted operating margin contraction of 61 basis points.
Looking ahead, the Zacks Consensus Estimate for fiscal 2027 earnings per share indicates a 0.4% increase to $11.09, with consensus revenues pegged at $6.37 billion suggesting 7.4% growth from fiscal 2026 reported numbers. The company has a market capitalization of $21.18 billion and an earnings yield of 5.1%, which is well above the industry's negative 2.2% yield. STE shares have lost 9.6% over the past year compared to the industry's 4.2% decline, while the S&P 500 composite has risen 32.5% during the same period. The company holds a Zacks Rank #3 (Hold) rating.
📈 STE Healthcare revenues rose 7% to $1.14B, while AST services grew 9%.
⚠️ FX volatility and new tariffs threaten margins by adding ~$46M in 2026 costs.
💰 Company holds a $21.18B market cap with a strong 5.1% earnings yield.
📈 STERIS plc's STE Healthcare segment is experiencing strong market adoption of its infection prevention consumables and capital equipment.
💰 The Applied Sterilization Technologies (AST) segment is benefiting from robust service revenues, which is encouraging growth.
⚠️ Macroeconomic volatilities and unfavorable foreign exchange rates raise concerns for the company's reported results.
📉 Over the past year, STE shares lost 9.6% compared with the industry's 4.2% decline and the S&P 500's 32.5% rise.
💵 The company has a market capitalization of $21.18 billion and an earnings yield of 5.1%, well above the industry's negative 2.2%.
📊 STE delivered an average earnings surprise of 0.9% for the trailing four quarters.
🏥 Healthcare revenues increased 7% to $1.14 billion in the fiscal fourth quarter, with service up 9% and consumables up 7%.
🔧 Capital equipment backlog ended just under $400 million, with orders up 2% in the fiscal fourth quarter.
🌍 The AST segment operates a worldwide network of over 50 contract sterilization and laboratory facilities.
📈 For fiscal 2026, AST revenues are projected to increase 10%, aligning with the company's longer-term expectations.
💸 In the fourth quarter, capital equipment revenues for AST declined 62% while services revenue grew 10%.
🌐 Foreign exchange volatility can impact reported results and competitiveness due to a meaningful portion of revenues generated outside the U.S.
📉 Global macro pressure and healthcare cost-containment efforts continue to weigh on spending and pricing in the industry.
🛑 Tariffs implemented by the new U.S. government are expected to add approximately $46 million in costs for 2026, trimming margins by 80 basis points.
📉 Selling, general and administrative expenses increased 5.4%, while research and development expenses rose 4%.
🔮 The Zacks Consensus Estimate for fiscal 2027 earnings per share indicates a 0.4% increase to $11.09.
📈 The consensus mark for fiscal 2027 revenues is pegged at $6.37 billion, suggesting 7.4% growth from the fiscal 2026 reported number.
🔍 Other better-ranked stocks in the broader medical space include Globus Medical (GMED), Alcon (ALC), and Phibro Animal Health (PAHC).
🚀 Globus Medical has a Zacks Rank #1 (Strong Buy) with shares rallying 28.1% against the industry's decline over the past year.
💰 Alcon carries a Zacks Rank #2 (Buy) with an earnings yield of 5.2% against the industry's negative 2.2%.
🐾 Phibro Animal Health has an estimated long-term earnings growth rate of 21.5% compared with the industry's 12.1%.
Bullish Signals
STERIS Healthcare revenue rose to $4.21 billion with 12% service growth.
AST segment surpassed $500M operating profit and $1B revenues.
AST fiscal 2026 revenues projected to increase by 10%.
STERIS earnings yield of 5.1% beats industry negative 2.2%.
Average earnings surprise of 0.9% over trailing four quarters.
Capital equipment backlog near $400 million with 2% order growth.
Risk Factors
STERIS shares fell 9.6%, underperforming industry and S&P 500.
Foreign exchange volatility risks persist due to global revenue exposure.
Macroeconomic pressures and cost containment weigh on spending power.
Tariffs expected to add $46M costs in 2026, trimming margins 80bps.
Selling expenses rose 5.4% and R&D up 4%, contracting adjusted margin 61bps.
Bullish Signals
STERIS plc's Healthcare segment delivered strong revenue growth, with full-year revenues rising to $4.21 billion and service revenues increasing by 12%.
The Applied Sterilization Technologies (AST) segment reached a significant milestone by surpassing $500 million in operating profit while generating over $1 billion in revenues.
For fiscal 2026, AST revenues are projected to increase by 10%, aligning with the company's longer-term expectations for sustained growth.
STERIS has an earnings yield of 5.1%, which is well above the industry's negative 2.2% yield, indicating strong profitability relative to peers.
The company delivered an average earnings surprise of 0.9% over the trailing four quarters, demonstrating consistent performance against analyst estimates.
Capital equipment backlog ended just under $400 million with orders up 2% in the fiscal fourth quarter, signaling robust future demand.
Despite macroeconomic headwinds, the company expects a slightly favorable foreign exchange impact for its international operations.
Risk Factors
STERIS shares have lost 9.6% over the past year, significantly underperforming the industry's 4.2% decline and the S&P 500's 32.5% rise.
The company faces meaningful foreign exchange volatility risks due to a large portion of revenues and costs being generated outside the United States.
Global macroeconomic pressures and healthcare cost-containment efforts are weighing on spending and pricing power for the company.
Implementation of tariffs by the new U.S. government is expected to add approximately $46 million in incremental costs in 2026, trimming margins by 80 basis points.
Operating expenses have escalated significantly, with selling, general, and administrative expenses increasing 5.4% and research and development expenses rising 4%.
These combined cost pressures led to an adjusted operating margin contraction of 61 basis points.
STERIS (NYSE: STE) reported a stronger fiscal 2026 overall despite a lighter fourth quarter, with executives pointing to record annual revenue of approximately $6 billion and resilient procedure demand. Fourth-quarter revenue grew 7% as reported, while constant currency organic revenue increased 5%, driven by volume and pricing gains that offset higher tariffs and inflation. Adjusted net income from continuing operations was $278.3 million, with adjusted diluted earnings per share rising 3% to $2.83. Fiscal 2026 adjusted earnings per rose 10% to $10.17, even as tariffs reduced margins by 80 basis points. Free cash flow for fiscal 2026 was $982.9 million, and the company ended the year with $1.9 billion in total debt and a gross debt-to-EBITDA ratio of about 1.2 times.
Segment performance was led by Healthcare growth, which increased 9% as reported and 8% on a constant currency organic basis, generating $4 billion in revenue and $1 billion in operating income for the year. The Applied Sterilization Technologies segment grew 10% as reported, though results were lighter than expected due to second-half softness and severe U.S. snowstorms early in the calendar year. Life Sciences grew 9% as reported, benefiting from a 15% increase in capital equipment growth as customers resumed investment after a prior downturn. The company expects fiscal 2027 as-reported revenue growth of 7% to 8%, with constant currency organic revenue growth of 6% to 7%. Fiscal 2027 adjusted earnings per share are expected to be $11.10 to $11.30, representing 9% to 11% growth over fiscal 2026.
Capital allocation includes a quarterly dividend increase to $0.63, $225 million in share repurchases, and a new $1 billion buyback authorization. The company completed two tuck-in acquisitions in Healthcare expected to contribute about $45 million of combined revenue in fiscal 2027. STERIS plans fiscal 2027 capital expenditures of $375 million and free cash flow of $850 million. A new sterility assurance manufacturing plant is planned for Mentor, Ohio, intended to consolidate existing U.S. production into a state-of-the-art facility with an expected investment of about $60 million over two years.
📈 Fiscal 2026 revenue hit $6B driven by mid-to-high single-digit growth across segments.
💰 EPS rose 3% to $2.83 in Q4 despite higher tax rates and inflation impacts.
🔬 Healthcare and Life Sciences grew 9-15%, with a new Ohio plant launching in 2027.
📅 Fiscal 2027 guidance projects 7-8% revenue growth and EPS between $11.10-$11.30.
💵 Company approved $1B buyback authorization and raised dividend for the 20th year.
📈 STERIS reported record fiscal 2026 revenue of approximately $6 billion, driven by mid- to high-single-digit growth despite a lighter fourth quarter.
💰 Fourth-quarter revenue grew 7% as reported, with constant currency organic revenue increasing 5% due to volume and pricing gains.
📉 Gross margin decreased 30 basis points to 44%, while EBIT margin reached 24.2%, the highest for fiscal 2026 but down from the prior year due to inflation and tariffs.
💵 Adjusted net income was $278.3 million with diluted earnings per share of $2.83, up 3% year-over-year despite higher tax rates limiting growth.
📊 CEO Dan Carestio highlighted a 10% rise in adjusted earnings per share to $10.17 for fiscal 2026, even as tariffs reduced margins by 80 basis points.
💧 Free cash flow for fiscal 2026 totaled $982.9 million, supported by higher earnings and capital expenditures of $369 million.
🏦 The company ended the year with $1.9 billion in total debt and a gross debt-to-EBITDA ratio of about 1.2 times, below its target range.
🏥 Healthcare segment revenue grew 9% as reported, led by 12% growth in service revenue and a capital equipment backlog just under $400 million.
🧪 Applied Sterilization Technologies (AST) grew 10% as reported but faced softer results due to U.S. snowstorms and cautious MedTech inventory management.
🔬 Life Sciences segment grew 9% with significant capital equipment growth of 15% as customers resumed investment after a prior downturn.
📅 For fiscal 2027, STERIS expects revenue growth of 7% to 8% and adjusted earnings per share between $11.10 and $11.30.
⚠️ Management adopted a conservative view on AST for fiscal 2027 due to difficult comparisons and ongoing inventory reductions in the MedTech sector.
📉 Tariff spending is expected to remain flat at $60 million to $65 million in fiscal 2027, with no tariff refunds included in guidance.
💰 The quarterly dividend increased by $0.06 to $0.63, marking the 20th consecutive year of dividend growth for the company.
🔄 STERIS approved a new $1 billion share buyback authorization and plans annual repurchases between $200 million and $300 million.
🤝 Two tuck-in acquisitions in Healthcare are expected to contribute about $45 million in combined revenue starting in fiscal 2027.
🏭 The company plans to build a new sterility assurance manufacturing plant in Mentor, Ohio, intended to consolidate U.S. production.
🔧 The new Ohio facility is projected to cost about $60 million over two years and become operational by the end of calendar 2027.
📈 Capital expenditures for fiscal 2027 are planned at $375 million, with priorities shifting toward automation and capacity expansion.
🌍 STERIS operates as a global provider of infection prevention and contamination control products for healthcare, life sciences, and pharmaceutical industries.
Bullish Signals
STERIS reported record FY2026 revenue of approximately $6 billion.
Adjusted EPS rose 10% to $10.17 despite margin pressures.
Healthcare segment grew 9% with $4 billion in revenue.
Life Sciences operating profit exceeded $250 million for the first time.
STERIS raised quarterly dividend by $0.06 to $0.63.
Company announced new $1 billion share buyback authorization.
Risk Factors
Lower gross margin and higher 25.4% tax rate limited Q4 net income growth.
Applied Sterilization Technologies missed expectations due to softness and snowstorm impacts.
Conservative AST 2027 growth view driven by customer inventory management.
Inventory reductions in MedTech segment constrain near-term demand visibility.
STERIS reported record annual revenue for fiscal 2026, with total company revenue reaching approximately $6 billion.
Adjusted earnings per rose 10% to $10.17, demonstrating strong profitability despite margin pressures from tariffs.
The Healthcare segment grew 9% as reported and generated $4 billion in revenue and $1 billion in operating income for the year.
Capital equipment backlog in the Healthcare segment reached just under $400 million, with orders up 2% in the fourth quarter.
Life Sciences exceeded $250 million in operating profit for the first time, driven by a 15% increase in capital equipment growth as customers resumed investment.
Fiscal 2027 outlook includes mid- to high-single-digit organic revenue growth and expected EBIT margin expansion of approximately 50 basis points.
Adjusted earnings per share are expected to grow 9% to 11% in fiscal 2027, with targets set between $11.10 and $11.30.
The company increased its quarterly dividend by $0.06 to $0.63, marking its 20th consecutive year of dividend growth.
STERIS announced a new $1 billion share buyback authorization and plans consistent annual buybacks in the range of $200 million to $300 million.
The company completed two tuck-in acquisitions expected to contribute about $45 million of combined revenue in fiscal 2027.
Risk Factors
Adjusted net income growth was limited in the fourth quarter due to a lower gross margin and a higher effective tax rate of 25.4%, up from 23.5% the prior year.
The Applied Sterilization Technologies segment delivered results lighter than expected, citing second-half softness and severe U.S. snowstorms early in the calendar year that impacted fourth-quarter services revenue.
Management is taking a more conservative view on AST growth for fiscal 2027 due to MedTech customers carefully managing inventory levels and difficult first-half comparisons.
The company noted some inventory reduction across the broader MedTech customer segment, which could constrain near-term demand visibility despite underlying procedure rates remaining resilient.
Fiscal 2027 guidance assumes a flat tariff spending range of $60 million to $65 million with no inclusion of potential tariff refunds, creating downside risk if trade policy shifts.
Steris plc (ticker STE) has attracted investor attention due to sustained revenue growth and a constructive outlook from Wall Street analysts, positioning it as a defensive healthcare name with recurring revenue characteristics. As of May 15, 2026, the stock closed at $211.80, significantly below the average analyst price target of $275.67 established by four analysts, with high and low targets ranging from $263.00 to $295.00. Market commentary highlights that the company sells products and services essential for cleaning, sterilizing, and protecting medical instruments, a business model that generates substantial recurring revenue from consumables, service agreements, and installed equipment support rather than relying solely on one-time sales.
This recurring revenue mix is viewed as attractive because it provides visibility into healthcare utilization trends, allowing the company to maintain demand even if broader capital spending slows down. Recent third-party coverage noted revenue growth exceeding 9% in the latest earnings context, signaling solid demand relative to the prior year and framing Steris as a steady growth story rather than a high-volatility trade. The company serves a broad base of end markets including acute-care hospitals, ambulatory surgery centers, and other healthcare facilities, which helps diversify exposure across different aspects of clinical procedures and capital replacement cycles within the United States healthcare system.
While the stock offers exposure to the hospital supply chain with industrial-like margins, analysts are closely monitoring margin trends, product mix, and execution across service and equipment categories, as these factors often dictate valuation more than headline revenue growth alone. A key question for investors is whether this revenue momentum can be sustained if hospital budgets tighten or procedure volumes normalize, given that the business remains exposed to procurement timing, pricing pressure, and general healthcare activity cycles. Ultimately, the next major catalyst for the stock is expected to come from Steris's own earnings reports and guidance updates, which will clarify whether the recent growth trajectory and elevated analyst price targets are sustainable.
🏥 Steris manufactures medical equipment serving US hospitals and surgery centers globally.
💰 Stock closed at $211.80 with an analyst average price target of $275.67.
📈 Revenue grew over 9% driven by recurring consumables and service agreements.
🏥 Steris plc is a medical equipment manufacturer serving hospitals, surgery centers, and healthcare facilities in the US.
💰 The stock closed at $211.80 on May 15, 2026, according to MarketBeat data.
📈 Wall Street analysts set an average price target of $275.67, with a range between $263.00 and $295.00.
🔁 A significant portion of Steris's revenue comes from recurring consumables, service agreements, and equipment support rather than one-time sales.
🛡️ This recurring revenue model makes the stock less cyclical compared to many industrial names, as healthcare spending on infection prevention remains steady even when capital budgets slow.
💹 Recent market coverage indicated revenue growth exceeding 9% in the latest earnings period, signaling solid demand relative to the prior year.
🏭 The company sells sterilization systems, infection-prevention products, surgical equipment, and service contracts linked to hospital operating schedules.
🔍 Analysts cover a broad base of end markets including acute-care hospitals, ambulatory surgery centers, and other healthcare facilities.
📉 Investors are monitoring margin trends, product mix, and execution across categories as much as headline revenue growth.
⚠️ An open question remains whether current revenue momentum can sustain if hospital budgets tighten or procedure growth normalizes.
📅 Analyst price targets may change after quarterly releases or guidance updates, making earnings reports key upcoming catalysts.
🌎 Steris trades on the NYSE and offers exposure to the US healthcare infrastructure supply chain and hospital equipment replacement cycles.
📊 The company performs as a defense-style healthcare name, attracting institutional investors seeking stability tied to procedure volumes.
Bullish Signals
Steris achieved over 9% revenue growth.
Stock closed at $211.80 with $275.67 target.
High of $295.00 and low of $263.00 show bullish consensus.
Business relies on recurring revenue from consumables and services.
Diversified exposure to hospitals and surgery centers.
Risk Factors
Stock trades at $211.80 vs $275.67 target price.
Revenue sustainability risks from tighter hospital budgets.
Valuation uncertain after earnings releases or guidance updates.
Margins pressured by procurement timing and healthcare pace.
Bullish Signals
Steris plc recently achieved revenue growth of more than 9% in the latest earnings context, signaling that demand remained solid relative to the prior year.
The stock closed at $211.80 on 05/15/2026 with an average Wall Street price target of $275.67 based on four analysts, indicating a significant upside potential.
A high analyst price target of $295.00 and a low of $263.00 suggest a strong bullish consensus among market watchers.
The company's business model is attractive due to its reliance on recurring revenue from consumables, service agreements, and installed equipment support rather than one-time transactions.
Steris benefits from broad exposure to multiple end markets, including acute-care hospitals, ambulatory surgery centers, and other healthcare facilities, diversifying its revenue streams.
The stock is framed as a steady growth story that remains relevant on institutional screens even when broader capital spending slows in the industrial sector.
Risk Factors
The current stock price of $211.80 is significantly below the average Wall Street analyst target of $275.67, implying a potential downside gap that may not reflect underlying fundamentals immediately.
One open question remains regarding whether recent revenue momentum can be sustained if hospital budgets tighten or procedure growth normalizes in the future.
The stock's valuation and price targets are subject to rapid change after quarterly earnings releases or guidance updates from management, introducing uncertainty for short-term investors.
Despite a focus on recurring revenue, Steris remains exposed to procurement timing, pricing pressure, and the overall pace of healthcare activity which can impact margins.
STERIS Inc. (NYSE:STE) reported first quarter results for fiscal year 2026 that aligned with Wall Street revenue expectations but slightly missed adjusted EPS guidance. The company posted Q1 revenue of $1.59 billion, a 7.3% year-over-year increase, which matched analyst consensus estimates exactly. Adjusted earnings per share came in at $2.83 versus an expected $2.85, representing a 0.7% miss relative to consensus. However, adjusted EBITDA margin expanded to 23.5%, significantly exceeding the previously cited guidance of approximately 19.6% for the quarter and demonstrating resilience against external headwinds.
Management highlighted three primary drivers behind the performance: robust service revenue growth, which rose 12% year-over-year, gains in consumables sales, and a stabilization within the capital equipment business. Service revenue expansion helped offset inflationary pressures and supply chain challenges, while consumables sales increased by 7-8% due to effective commercial execution and portfolio breadth. The capital equipment segment reduced quarterly volatility observed in recent periods with solid backlog levels despite normalizing shipment cycles. Notably, severe winter weather disruptions impacted Applied Sterilization Technologies (AST) segment volumes and service activity, creating short-term revenue softness that management expects will normalize as customer inventories adjust and weather effects dissipate.
Looking ahead to fiscal 2027, management provided guidance for adjusted EPS of $11.20 at the midpoint, beating analyst consensus by 1.1%. The outlook assumes mid- to high-single-digit organic growth driven by continued strength in service and consumables, benefits from tuck-in acquisitions, and incremental automation gains. CEO Dan Carestio emphasized the company's commitment to enabling customer procedural growth through partnerships, while CFO Karen Burton noted that tariff expenses are expected to stabilize at current levels and that freight recovery pricing should mitigate logistics volatility. The company plans to leverage expanded manufacturing capacity and maintain a measured approach to share buybacks amidst ongoing cost pressures including inflation and tariffs.
📈 Revenue grew 7.3% YoY to $1.59B, matching Wall Street expectations.
⚠️ Adjusted EBITDA missed estimates significantly while operating margins expanded to 19.9%.
💻 Service and consumables revenue surged, offsetting weather disruptions in the AST segment.
🤖 Management is investing in AI workflows and stable capital equipment backlogs.
💲 Stock price rose to $207.19 after surpassing forward EPS guidance.
📈 Steris reported Q1 CY2026 revenue of $1.59 billion, matching Wall Street expectations with 7.3% year-on-year growth.
💰 Adjusted earnings per share reached $2.83, slightly missing the analyst consensus estimate of $2.85.
⚠️ Adjusted EBITDA came in at $373.1 million, representing a 17.9% miss against estimates and lowering margins to 23.5%.
📊 Forward guidance for fiscal year 2027 adjusted EPS is set at $11.20, surpassing analyst expectations by 1.1%.
📈 Operating margin expanded significantly to 19.9%, up from 14.6% in the prior-year quarter.
💻 Service revenue grew robustly by 12%, helping offset cost inflation and supply chain challenges.
⚡ Consumables sales increased 7-8% driven by effective commercial execution and broader portfolio offerings.
🔧 Capital equipment business stabilized with reduced volatility and solid backlog levels despite normalized shipment cycles.
🌦️ Severe winter weather disrupted AST segment operations, causing short-term softness in service revenue.
🤖 Management is investing in AI-driven service workflows to enhance productivity and customer experience.
💲 CFO Karen Burton expects tariff expenses to remain flat with moderate assumptions for energy and freight costs.
📉 Freight recovery pricing strategies are expected to mitigate most volatility in logistics expenses.
🏥 Healthcare and Life Sciences segment expansion continues to be a key growth driver for the company.
💼 CEO Dan Carestio emphasized commitment to partnering with customers to enable procedural growth needs.
🔄 Stock price rose to $207.19 following earnings, up from $201.85 prior to the announcement.
Bullish Signals
Q1 CY2026 sales up 7.3% YoY to $1.59 billion.
Operating margin expanded to 19.9%, a significant increase from 14.6%.
Adjusted EPS guidance for FY2027: $11.20, beating estimates by 1.1%.
Capital equipment business stabilizing with solid backlog levels.
Steris shares rose to $207.19 following earnings.
Risk Factors
Non-GAAP profit missed estimates by 0.7% despite meeting revenue.
Adjusted EBITDA was 17.9% below the estimated $454.6 million.
Severe winter weather hurt AST segment procedural volumes and activity.
External pressures like inflation and tariffs impact company margins.
Technology upgrades for automation and AI carry execution risks.
Bullish Signals
Steris met Wall Street's revenue expectations in Q1 CY2026, with sales up 7.3% year-over-year to $1.59 billion.
Operating margin expanded to 19.9%, a significant increase from 14.6% in the same quarter last year, demonstrating effective cost management and pricing power.
Adjusted EPS guidance for fiscal year 2027 is set at $11.20 at the midpoint, beating analyst estimates by 1.1% and signaling management's confidence in future performance.
Service revenue rose 12%, providing strong momentum and helping to offset inflationary pressures within the Healthcare and Life Sciences segments.
Consumables sales increased by 7-8% due to effective commercial execution and successful capture of additional market share among healthcare providers.
Capital equipment business is stabilizing with reduced quarterly volatility and solid backlog levels as shipment cycles normalize, indicating a maturing segment.
Management expects incremental benefits from recent tuck-in acquisitions and investments in automation and AI-driven service workflows that will support productivity and customer experience.
Freight recovery pricing strategies are mitigating logistics expenses, while tariff expenses are projected to remain stable according to CFO Karen Burton.
The AST segment is expected to accelerate growth in the second half of the year as weather-related disruptions subside and med tech customer inventories normalize.
Steris shares rose to $207.19 following earnings, reflecting the market's positive response to margin expansion and resilient revenue performance.
Risk Factors
Non-GAAP profit of $2.83 per share missed analyst consensus estimates by 0.7%, despite revenue meeting expectations.
Adjusted EBITDA came in at $373.1 million, representing a 17.9% miss against estimates of $454.6 million.
Severe winter weather disruptions negatively impacted procedural volumes and service activity in the AST segment.
Management acknowledged ongoing external pressures including inflation and tariffs affecting margins.
The company faces execution risks related to multi-year technology upgrades for automation and AI initiatives.
Future growth is constrained by a cautious outlook on the pace of recovery in the AST segment due to inventory normalization challenges.
The market capitalization of $19.8 billion reflects investor concerns about cost headwinds balancing against margin expansion efforts.
Steris plc (STE) has authorized a $1 billion share buyback program following a record fiscal 2026 performance that included 9% revenue growth and 7% organic growth on a constant currency basis, with President, CEO, and Director Daniel Carestio noting the company delivered 10% adjusted earnings per share growth despite an 80 basis points increase in interest rates. The company is projecting fiscal 2027 to see continued expansion with revenue growth expected between 7% and 8% and earnings per share ranging from $11.10 to $11.30. This guidance reflects ongoing confidence in the business outlook even as macroeconomic factors like interest rate changes are factored into financial planning.
The AI-generated insights note that the buyback authorization comes after another successful quarter, signaling management's commitment to returning capital to shareholders alongside organic growth initiatives. Seeking Alpha's disclaimer indicates this content is automatically generated and not reviewed by humans, though the core financial data presented aligns with standard earnings call disclosures regarding fiscal year targets and board actions. The stock ticker is appropriately focused as the primary subject of the piece, making it relevant for investors tracking Steris' capital allocation strategies and growth trajectory.
📈 STERIS plc recorded a record year with 9% total revenue growth.
💰 Adjusted EPS grew 10%, while organic revenue rose 7% constant currency.
✅ Board authorized a $1 billion share buyback program.
🔮 Management forecasts 7-8% revenue and $11.10-$11.30 EPS for 2027.
📊 STERIS plc reported fiscal 2026 as a record year with 9% total revenue growth.
🌍 Organic revenue grew by 7% on a constant currency basis during the period.
📅 CEO Daniel Carestio highlighted fiscal 2026 performance in comments during the earnings call.
🤲 The board of directors has authorized a new $1 billion share buyback program.
📈 Management forecasts 7%-8% revenue growth for fiscal 2027.
💹 EPS is projected to range between $11.10 and $11.30 in fiscal 2027.
⚠️ The article notes an 80 basis point headwind was faced during the current period.
Bullish Signals
Steris plc (STE).
Risk Factors
AI-generated analysis on Seeking Alpha without human review.
Lacks detailed financial context for fiscal 2026.
Bullish Signals
Steris plc (STE) reported fiscal 2026 as another record year with 9% revenue growth, demonstrating strong top-line performance.
The company achieved 10% adjusted earnings per share growth in fiscal 2026, highlighting robust profitability.
Management anticipates fiscal 2027 will see revenue grow at a rate of 7%-8%, projecting sustained expansion for investors.
Risk Factors
The analysis is flagged as AI-generated by Seeking Alpha without human review, indicating potential unreliability in the specific earnings guidance provided.
The article lacks detailed financial context for fiscal 2026 beyond the summary numbers, making it difficult to assess if the growth rate of 9% is sustainable compared to inflation or market peers.
STERIS plc (NYSE: STE) announced its financial results for the fourth quarter and full year ended March 31, 2026, on May 11, 2026. Full-year fiscal 2026 revenue from continuing operations increased 9% to $5.9 billion compared with $5.5 billion in the prior year, driven by constant currency organic revenue growth of 7%. Reported diluted earnings per share (EPS) grew to $7.93 while adjusted EPS reached $10.17. In the fourth quarter alone, revenue rose 7% to $1.6 billion and adjusted net income increased to $278.3 million.
The company's Healthcare segment contributed significantly to this growth with total reported revenue rising 7% in the fourth quarter, fueled by a 9% increase in service revenue and 7% growth in consumables. However, tariff costs and inflation pressured operating margins despite volume improvements. Meanwhile, the Applied Sterilization Technologies segment saw capital equipment revenue drop 62% due to lower volumes, though services grew 10%. The Life Sciences segment remained robust with a 9% revenue increase led by a strong 19% surge in capital equipment sales.
Looking ahead, management forecasts fiscal 2027 as reported revenue growth of 7-8%, excluding tuck-in acquisitions which may add to the Healthcare segment. They expect constant currency organic revenue growth of 6-7% and adjusted EPS between $11.10 and $11.30, representing a 9-11% increase over fiscal 2026 results. To return capital to shareholders, the Board approved a new $1 billion share repurchase program. The company also highlighted that free cash flow for fiscal 2026 improved significantly to $982.9 million from $787.2 million in the previous year.
📈 Fiscal 2026 revenue hit $5.9 billion, a 9% year-over-year increase.
💰 Diluted EPS reached $7.93 with FCF rising to $982.9 million.
🏛️ A new $1 billion share repurchase program was officially approved.
🔮 Fiscal 2027 revenue is projected to grow 7–8% compared to last year.
⭐ CEO calls this a record year driven by strong volume growth.
STERIS plc reported full year fiscal 2026 revenue from continuing operations of $5.9 billion, representing a 9% increase from the prior year.
Constant currency organic revenue growth for the full year fiscal 2026 was 7%, driven by growth in healthcare and applied sterilization technologies segments.
Diluted EPS from continuing operations reached $7.93 on an as-reported basis, while adjusted EPS per diluted share increased to $10.17.
The company announced a new $1 billion share repurchase program approved by the board of directors.
Fourth quarter revenue specifically grew 7% year-over-year to reach $1.6 billion from continuing operations.
Healthcare segment operating income improved due to volume and price gains, though it was partially offset by tariffs and inflation.
Applied Sterilization Technologies (AST) saw a 62% decline in capital equipment revenue, which contrasted with strong service revenue growth of 10%.
Life Sciences revenue increased 9% in the fourth quarter, driven primarily by a 19% surge in capital equipment sales.
Free cash flow for fiscal 2026 rose to $982.9 million, up from $787.2 million in the previous fiscal year.
CEO Dan Carestio described fiscal 2026 as a record year, citing diversified customer base and procedural volume growth as key drivers.
The company provides a full year fiscal 2027 outlook with as-reported revenue expected to rise 7-8% compared to fiscal 2026.
Adjusted earnings per diluted share for fiscal 2027 are projected between $11.10 and $11.30, reflecting growth of 9-11%.
STERIS plc (NYSE: STE) announced on May 7, 2026, that Pierre Boulud has been appointed to its Board of Directors, effective May 5, 2026. The appointment was confirmed by Mohsen Sohi, Chairman of STERIS, who praised Boulud's leadership experience, global perspective, strategic acumen, and operational expertise as valuable assets to the board. Pierre Boulud currently serves as the CEO of bioMérieux, a position he has held since 2023. He previously joined bioMérieux in 2016 as Corporate Vice President for the Asia Pacific Region before being promoted to Chief Operating Officer in 2020. His background includes fourteen years at Ipsen, where he served as Executive Vice President of Specialty Care Commercial Operations, and prior work as a strategic consultant at The Boston Consulting Group.
This addition to the board brings significant experience from the diagnostics and specialty care sectors, complementing STERIS's focus on infection prevention and healthcare products. The announcement is part of standard corporate governance updates, highlighting the company's emphasis on strategic leadership and operational expertise within its leadership team. As with all such filings, the press release includes a standard cautionary statement regarding forward-looking information, outlining various risks related to operating costs, integration of acquisitions, regulatory compliance including ethylene oxide litigation, international trade barriers, and market competition that could impact the company's financial results and performance.
📋 Pierre Boulud appointed to STERIS Board effective May 5, 2026.
🧬 He is currently CEO of bioMérieux and has decades of leadership experience.
⚠️ Company warns of risks including litigation, market competition, currency fluctuations, and labor disruptions.
📋 STERIS plc announced the appointment of Pierre Boulud to its Board of Directors effective May 5, 2026.
👔 Pierre Boulud currently serves as CEO of bioMérieux, a global leader in in vitro diagnostics.
🌍 Prior to his current role, Boulud joined bioMérieux in 2016 and held various leadership positions including Head of Asia Pacific Region and COO.
💼 Before bioMérieux, Boulud spent fourteen years at Ipsen, most recently as Executive Vice President of Specialty Care Commercial Operations.
🎓 Boulud previously worked as a strategic consultant at The Boston Consulting Group early in his career.
👨💼 Mohsen Sohi, Chairman of STERIS, welcomed Boulud to the board citing his leadership experience and operational expertise.
🏥 STERIS is a leading global provider of products and services focused on infection prevention and patient care.
⚠️ The company issued a cautionary statement regarding forward-looking information under the Private Securities Litigation Reform Act of 1995.
📉 Potential risks to STERIS include operating costs, pricing pressure, customer loss, business disruption, and integration challenges from acquisitions.
⚖️ Legal and regulatory risks mentioned include potential impacts from pending litigation such as ethylene oxide cases.
🌐 International risks factor into the forecast, including military conflicts, economic downturns, currency fluctuations, and trade barriers.
📉 Competition within the industry may exert pressure on pricing strategies or lead to decreasing demand for products and services.
💰 Financial risks include debt levels limiting flexibility, credit availability issues, and potential failures to realize anticipated acquisition synergies.
🛑 Labor-related disruptions such as strikes or unsuccessful union negotiations could adversely affect operations.
Bullish Signals
STERIS appointed Pierre Boulud to its Board effective May 5, 2026.
Boulud brings bioMérieux CEO leadership since 2023.
Former Ipsen executive and BCG strategic consultant.
Risk Factors
Operating costs and inflation risks threaten profit margins.
Acquisitions carry risks of unknown liabilities and integration issues.
Changes in tax laws could increase consolidated tax liabilities.
Ethylene oxide litigation delays product introductions and incurs uncovered costs.
Global unrest, conflicts, and currency fluctuations threaten operations.
Bullish Signals
STERIS announced the appointment of Pierre Boulud to its Board of Directors, effective May 5, 2026, recognizing his strong leadership experience, global perspective, strategic acumen, and operational expertise.
Pierre Boulud brings extensive industry credibility as the current CEO of bioMérieux, a world leader in in vitro diagnostics, a role he has held since 2023.
His diverse background includes significant tenure at Ipsen, where he served as Executive Vice President of Specialty Care Commercial Operations with global sales responsibilities, and his previous experience as a strategic consultant at The Boston Consulting Group.
Risk Factors
STERIS faces potential erosion of profit margins due to operating costs and pressure on pricing, including risks related to inflation.
The company carries significant risk from acquiring businesses which could result in unknown liabilities, impairments, or unexpected integration difficulties.
Changes in tax laws or interpretations in jurisdictions where STERIS operates could increase consolidated tax liabilities.
STERIS remains exposed to ongoing legal uncertainty regarding the ethylene oxide litigation, which may delay product introductions and incur uncovered costs.
International unrest, military conflicts, economic downturns, and currency fluctuations present threats to global operations.
There is a risk of delays in order receipts or shipment cancellations impacting revenue recognition and cash flow.
Increasing competition within the industry may exert downward pressure on pricing strategies and reduce product demand.
The company faces potential operational disruptions from labor-related issues such as strikes or unsuccessful union negotiations.
Steris PLC shares slipped by 1.14% to close at $214.40 on Friday, a day characterized by mixed trading across the broader stock market. During this session, the S&P 500 Index rose modestly to 7,230.12, marking a 0.29% increase, while the Dow Jones Industrial Average fell to 49,499.27, representing a decline of 0.31%. Despite these losses on the day and closing nearly $55 below its peak, Steris PLC still outperformed many of its competitors. The stock remains significantly lower than its historical highs, currently trading 20.43% beneath its 52-week high of $269.44, a milestone it reached on January 16th.
The market data provided by FactSet reflects the real-time last sale values reported through Nasdaq for U.S. stock quotes, with intraday data subject to specific exchange requirements or at least a 15-minute delay. This context suggests that while the immediate sentiment for Steris was negative in isolation of the market movement, its relative performance against peers was positive enough to be noted as an outperformance despite the broader mixed session. The company continues to navigate trading conditions where it trades well below its all-time recent peak established earlier in the year.
📉 Steris shares dipped 1.14% to close at $214.40 Friday.
🗓️ Broader markets mixed with S&P 500 up and Dow down.
🔽 Stock trades 20.43% below its January 52-week high.
📉 Steris PLC shares closed the trading day lower, slipping 1.14% to reach a price of $214.40.
🗓️ This price decline occurred on Friday during an all-around mixed session for the broader stock market.
📊 The S&P 500 Index rose by 0.29% to close at 7,230.12 while the Dow Jones Industrial Average fell 0.31% to 49,499.27.
🔽 Current stock valuation shows Steris PLC trading 20.43% below its 52-week high of $269.44.
📆 The company previously reached its annual peak price on January 16th.
⚖️ Despite the specific losses on this day, the headline suggests the stock has outperformed competitors in a broader context.
Bullish Signals
Steris PLC (STE) outperformed its competitors, demonstrating relative strength despite the overall market volatility on Friday.
The stock demonstrated significant upside potential by trading well below its 52-week high of $269.44, achieved on January 16th, leaving approximately $55 per share of room for future appreciation.
Risk Factors
Steris PLC stock fell 1.14% to $214.40, recording a loss despite an overall mixed trading session in the broader market.
Shares are currently trading 20.43% below their 52-week high of $269.44, indicating significant downside from recent peak performance.
Steris PLC (STE) shares rose 1.99% to $216.88 on Thursday, April 30, 2026, ending a two-day losing streak despite underperforming competitors in an otherwise positive market session. The S&P 500 Index gained 1.02% to close at 7,209.01, while the Dow Jones Industrial Average climbed 1.62% to reach 49,652.14. Although the stock posted daily gains, its performance lagged behind industry peers during this trading day. The data reflects standard market movements reported by MarketWatch and FactSet, with intraday figures delayed at least 15 minutes per exchange requirements. No specific earnings or strategic developments were cited in the report to explain the relative underperformance compared to rival firms within the healthcare technology sector.
📈 Steris shares rose 1.99% to $216.88 on Thursday.
🏆 Stock ended a two-day losing streak with daily gains.
📉 Performance lagged behind the S&P 500 and Dow Jones averages.
- 📈 Steris PLC shares rose 1.99% to $216.88 on Thursday.
- 🏆 The stock ended a two-day losing streak with daily gains.
- 📉 Performance lagged behind the S&P 500 and Dow Jones averages.
- 🌍 Broader markets rallied as the S&P 500 climbed to 7,209.01.
- ⏱️ Intraday data is delayed by at least 15 minutes per exchange rules.
Bullish Signals
Shares of Steris PLC rose 1.99% to $216.88.
Stock ended two-day losing streak.
Bullish Signals
Shares of Steris PLC rose 1.99% to $216.88 on Thursday.
STERIS plc (STE), a Mentor, Ohio-based provider of infection prevention products and services with a market capitalization of $22.2 billion, is preparing to announce its fiscal fourth-quarter 2026 earnings. The company specializes in manufacturing and distributing sterilizers, washers, surgical tables, lights, equipment management systems, and endoscopy accessories. Ahead of the quarterly report, analysts project a diluted earnings per share (EPS) of $2.89 for Q4 2026, representing a 5.5% increase from the $2.74 EPS reported in the year-ago quarter. Historically, STE has either beaten or matched consensus estimates in each of its last four quarters, contributing to a generally bullish analyst sentiment.
Looking at the full-year and subsequent fiscal projections, analysts anticipate STE will report an annualized EPS of $10.22 for fiscal 2026, up 10.9% from $9.22 in fiscal 2025. The forward outlook suggests further growth, with EPS expected to rise 8% year over year to $11.04 in fiscal 2027. Recent performance indicates the stock has underperformed broader market benchmarks; specifically, STE shares have gained marginally over the past 52 weeks compared to the S&P 500 Index’s 33.6% gains and the State Street Health Care Select Sector SPDR ETF’s (XLV) 10.1% gains during the same period. Notably, on February 4, STE shares closed up by 1% after reporting Q3 results where revenue reached $1.50 billion, surpassing analyst estimates of $1.48 billion, while adjusted EPS of $2.53 met Wall Street forecasts.
Investor sentiment remains positive with an overall "Moderate Buy" rating among eight covering analysts; five recommend a "Strong Buy" and three rate it as "Hold." The average analyst price target is set at $287.33, indicating a potential upside of 30.9% from current levels. In the recent quarter mentioned, the company continued to align with financial expectations regarding revenue and earnings adjustments. All information provided in this article serves informational purposes, noting that the author did not hold positions in the securities discussed at the time of publication.
🏥 STERIS provides infection prevention products and services based in Mentor, Ohio.
💰 Analysts project Q4 EPS of $2.89, up 5.5% year-over-year from last year.
⚠ Stock has underperformed the S&P 500 and Health Care ETF over the past 52 weeks.
🏥 STERIS (STE) is a Mentor, Ohio-based company providing infection prevention products and services.
💰 The firm currently has a market capitalization of $22.2 billion.
📅 Analysts anticipate the company will report its fiscal fourth-quarter 2026 earnings soon.
🤑 EPS expectations for Q4 include a profit of $2.89 per share, representing a 5.5% increase from last year.
📈 STE has matched or beat consensus estimates in each of the last four quarters.
🎯 Full-year analysts project an EPS of $10.22, which is up 10.9% from fiscal 2025.
🚀 Long-term projections show EPS rising to $11.04 in fiscal 2027, an 8% year-over-year increase.
📉 Despite recent market gains, STE stock has underperformed the S&P 500 and Health Care ETF over the past 52 weeks.
📅 Previous Q3 results on Feb. 4 showed revenue of $1.50 billion, surpassing estimates.
⭐ Wall Street sentiment remains bullish with a "Moderate Buy" rating and significant upside potential.
👨💼 Five out of eight analysts covering the stock advise a "Strong Buy" rating while three recommend "Hold."
💵 The average analyst price target is $287.33, implying a 30.9% potential upside from current levels.
⚠️ Disclosure indicates author Neha Panjwani held no direct or indirect positions in the securities mentioned.
Bullish Signals
STERIS Q4 2026 EPS expected at $2.89, up 5.5% from prior year.
Company beat consensus estimates for four consecutive quarters.
Fiscal 2026 analyst EPS projection of $10.22 represents 10.9% growth.
Forward guidance shows expected EPS rising 8% to $11.04 in 2027.
Q3 earnings beat estimates with revenue of $1.5 billion and shares up 1%.
Five of eight analysts rate stock as 'Strong Buy' or 'Moderate Buy'.
Average analyst price target is $287.33, indicating 30.9% upside potential.
STERIS trailed XLV ETF's 10.1% sector gains over past year.
Three of eight analysts hold rather than buy recommendations.
Bullish Signals
STERIS is expected to report a profit of $2.89 per share on a diluted basis in Q4 2026, representing a 5.5% increase from the year-ago quarter's $2.74 per share.
The company has consistently beaten or matched consensus estimates in each of the last four quarters, demonstrating reliable performance.
For fiscal 2026, analysts project STE to report an EPS of $10.22, which is a 10.9% increase from $9.22 in fiscal 2025.
Forward guidance looks strong with expected EPS rising 8% year-over-year to $11.04 in fiscal 2027.
The recent Q3 earnings on Feb. 4 saw STE shares close up by 1%, with revenue of $1.50 billion surpassing analyst estimates of $1.48 billion.
Wall Street consensus is bullish on the stock, with five out of eight analysts rating it as a 'Strong Buy' and an overall 'Moderate Buy' rating.
The average analyst price target is set at $287.33, indicating a notable potential upside of 30.9% from current levels.
Risk Factors
STERIS stock has significantly underperformed the broader market, trailing the S&P 500 Index's 33.6% gains over the past 52 weeks with only marginal share appreciation.
The company also lagged behind its specific sector peers, failing to capture the State Street Health Care Select Sector SPDR ETF's (XLV) 10.1% gains during the same period.
Despite generally bullish analyst ratings, three out of eight analysts covering STE have given a "Hold" rating rather than a buy recommendation.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)